There are 61 healthcare IT products being developed for treating substance abuse disorders to meet the substantial demand for more effective therapies, according to a July 5 report from GlobalData Thematic Intelligence.
The products are classified as wearable medical devices, mobile health apps, and virtual and augmented reality technologies. They are designed to treat various conditions such as opioid use disorder, cannabis cravings, neonatal opioid withdrawal syndrome and nicotine addiction.
GlobalData predicts 27 of the products to receive regulatory approval by 2025, as 37 are in clinical trials and 24 are in early development. Seventeen of the products under development are wearable medical devices designed to help individuals manage their condition and track their progress.
Aside from wearable devices, there are 22 mobile health apps being designed to provide evidence-based treatments to individuals with substance use disorders. Apps within the digital therapeutics category aim to monitor the usage of pain medication and provide personalized plans to help decrease dependency and alleviate pain, according to the report.
There are four VR or AR medical devices in development focused on treating substance use disorders. The goal is to use VR headsets to implement cognitive behavioral therapy techniques within opioid treatment programs, according to the report.